Zacks Investment Research upgraded shares of EMERGENT BIOSOL (EBS) from UNDERPERFORM to NEUTRAL on March 11, 2013, with a target price of $15.90.
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops, manufactures and commercializes vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product, BioThrax (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on EMERGENT BIOSOL (EBS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment